e type a plus sign (+) inside	this This	Π
e type a plus sign (+) ilisioc		ட

PTO/SB/05 (08-00) red for use through 10/31/2002. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no persons are re	U.S. Patent and Trace	emark Office; U.S. DEPAF of information unless it di	RTMENT OF COMMERCE splays a valid OMB control number.	
	Attorney Docket No.	LEX-0126-USA		
UTILITY	First Inventor	Glenn Friedrich et a	. 0	
PATENT APPLICATION TRANSMITTAL		Nammalian Cells and	0	
IRANSIVITIAL	Title Novel Mutated II Express Mail label		300	
(Only for new nonprovisional applications under 37 CFR 1.53 (b))	No.	EL 747066882 US		
	ADDRESS TO:	Assistant Commission Box Patent Application	on no =	
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		Weekington DC 2023	31 () 🚃 [	
1   Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)	7. CD-RC Progra	m (Appendix)	ate, large table or Compute	
The status amolt antity status	8. Nucleotide and/or (if applicable, all	Amino Acid Sequence S	ubmission	
See 37 CFR 1.27.		nputer Readable For	m (CRF)	
3 X Specification [Total Pages   124   preferred arrangement set forth below)	L		1	
B righting title of the Invention		n Sequence Listing o		
- Descriptive de disconsission de la Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D	i. 🗆 co	-ROM or CD-R (2 copies)	); or	
	i.i. 🗵 ps	per		
or a computer program listing appendix	c. Sta	tements verifying ide	ntity of above copies	
Brief Summary of the Invention     Brief Description of the drawings (if filed)	ACCOM	PANYING APPLIC	ATION PARTS	
- Detailed Description		nent Papers (cover s		
Claim(s)     Abstract of the disclosure	10. 37 CFR	3.73(b) Statement here is an assignee)	X Power of Attorney	
8	11. English	Translation Docume	nt (if applicable)	
Drawing(s)(35 U.S.C.113)   Total		ition Disclosure ent (IDS)/PTO-1449	Copies of IDS Citations	
5. Oath of Declaration [Total 2]				
13.   Preliminary American			IPEP 503)	
Copy from a prior application (37 CFR 163(d))  14. × (Should be specifically itemized)				
THE STICK OF INVENTOR(S)				
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR	16. Other:			
1.63(d)(2) and 1.33(b).	1.63(d)(2) and 1.33(b).			
Application Data Sheet. See 37 CFR 1.76				
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:				
Guardian in part (CIP) of prior application No.				
□ Divisional □ Divisional □ Continuation - in-past (curr) GrappArt Unit. GrappArt Unit. For application information. Examiner Exeminer For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an eath or declaration is supplied For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the accompanying continuation or divisional application and is hereby incorporated under Box 5th, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated under Box 5th, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated under Box 5th Continuation.				
under Box 5b, is considered a part of the annual				
by reference. 18. CORE	RESPONDENCE ADDRE	.55	respondence address below	
☑ Customer Number or Bar Code Label (Insert Custom	ner No. or Adacri par code labal here		respondence address services	
	24231			
Name Lance K. Ishimoto PAIDH, INDUMENTAL OFFICE				
4000 Research Forest Drive				
The Mandlands State		Zip	77381 (281) 364-0155	
City The Woodanias Telephone	(281) 863-3333	Fax	41866	
Registration No. (Attorney)				
Name (Printi Type)  Signature  Data January 31, 2001				

Lograture

| Date | January 31, 2001 | January 31,

(3

14

40

PTO/SB/35 (11-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Indominic Unice, U.S. Patent and Indominic Unice,

## REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)

danes to respon	a te a massimilia	numper.
First Named Inventor		Glenn Friedrich et al.
Title	Novel Mutated Mammalian Cells and	
Atty Docket Number		LEX-0126-USA

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

January 31, 2001

Signature

Lance K. Ishimoto
Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing.** 

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant must notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).

Burden Hour Statement: This collection of information is required by 37 CFR 1,213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentially is governed by 35 U.S.C. 122 and 37 1,14. This form is estimated to take 8 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount new jour are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.